Fig 1.
Flowchart of HIV-exposed infants followed in the Children’s Hospital Immunodeficiency Program (CHIP) clinic who were included in this study.
A) All infants, divided by type of maternal antiretroviral (ART) exposure; B) infants exposed to maternal integrase inhibitors (INSTI), divided by exposure or not to dolutegravir (DTG).
Table 1.
Demographic and HIV disease characteristics of INSTI- and non-INSTI-exposed mothers and infants.
Table 2.
Description of specific congenital anomalies that occurred among live-born infants of single gestation pregnancies, by organ system.
Fig 2.
Association between in utero exposure to any integrase inhibitor (INSTI) or dolutegravir (DTG) and the odds of having a congenital anomaly.
The reference group for first trimester DTG or any INSTI exposure is infants with first trimester non-INSTI ART exposure. The reference group for 2nd/3rd trimester DTG or any INSTI exposure is infants never exposed to INSTI ART.
Fig 3.
Percentage of infants ever exposed to an integrase inhibitor (INSTI) or non-INSTI regimen with each type of congenital anomaly.
Table 3.
Pregnancy outcomes of women receiving INSTI- and non-INSTI antiretroviral therapy.